Minister of economic affairs-
designate Lee Chih-kung (李世光) yesterday compared the impact of the OBI Pharma Inc (台灣浩鼎) controversy on the nation’s biotechnology industry to a “tsunami.”
OBI Pharma “definitely has an influence” on the biotech industry, Lee said during an interview with radio host Clara Chou (周玉蔻).
Photo: Huang Pei-chun, Taipei Times
“The impact looks like the beginning of a tsunami,” he added.
Lee said it was hard to say how long it would take for the industry to recover from the scandal, sparked by allegations of insider trading and conflict of interest at OBI Pharma, adding that it would depend on public sentiment.
Most developed countries value the biotech industry and understand that it requires long-term investment, he said.
“I am not trying to speak for OBI Pharma. The insider trading and conflict of interest allegations are indeed significant issues, but I think the public should seek the truth and look at the matter rationally,” Lee told reporters after the interview.
Lee declined to comment on Academia Sinica President Wong Chi-huey’s (翁啟惠) role in the case, saying that Wong should explain the matter to the public.
Wong is an internationally renowned academic, Lee said, adding that he does not think Wong’s involvement in the controversy is a “shame.”
However, the scandal and its effect on the public have affected the reputation of Academia Sinica, he said.
Local media reports have also revealed that Lee’s younger brother, Howard Lee (李世仁), is an independent board member of OBI Pharma and a member of Academia Sinica’s research and development results management committee — sparking a new round of speculation about conflict of interest.
C.K. Lee said that his brother’s situation cannot be classified as a conflict of interest, because the committee does not deal with individual companies.
Moreover, his brother does not receive remuneration as committee member, only a transportation allowance of NT$1,000 to NT$2,000 each time, C.K. Lee said.
However, he has asked his brother to consider resigning from OBI Pharma and the committee given his ministry post.
C.K. Lee also confirmed that he has dual citizenship, but said he had submitted an application to the American Institute in Taiwan (AIT) to give up his US citizenship, with an interview scheduled next week.
C.K. Lee, who is to take up his new post on May 20, is to visit Minister of Economic Affairs John Deng (鄧振中) on Monday to talk about the handover, the ministry said.
The 56-year-old said his biggest challenges in his new post would be finding ways to boost economic development, increase wages for young people and attract international talent to Taiwan.
His first task when he assumes office will be to promote development of the green energy sector in Taiwan in the hope of building a demand-oriented industry as soon as possible, Lee said.
He said he will also push for reform of the industrial sector, which has complained of water, electricity, land, and labor shortages.
Lee said he was made aware of the problems during his tour on April 28 of various industrial and commercial enterprises, which also mentioned other problems such as limited access to funding and consultancy services.
Additional reporting by CNA
The EU and US are nearing an agreement to coordinate on producing and securing critical minerals, part of a push to break reliance on Chinese supplies. The potential deal would create incentives, such as minimum prices, that could advantage non-Chinese suppliers, according to a draft of an “action plan” seen by Bloomberg. The EU and US would also cooperate on standards, investments and joint projects, as well as coordinate on any supply disruptions by countries like China. The two sides are additionally seeking other “like-minded partners” to join a multicountry accord to help create these new critical mineral supply chains, which feed into
For weeks now, the global tech industry has been waiting for a major artificial intelligence (AI) launch from DeepSeek (深度求索), seen as a benchmark for China’s progress in the fast-moving field. More than a year has passed since the start-up put Chinese AI on the map in early last year with a low-cost chatbot that performed at a similar level to US rivals. However, despite reports and rumors about its imminent release, DeepSeek’s next-generation “V4” model is nowhere in sight. Speculation is also swirling over the geopolitical implications of which computer chips were chosen to train and power the new
Elon Musk’s lieutenants have reached out to chip industry suppliers, including Applied Materials Inc, Tokyo Electron Ltd and Lam Research Corp, for his envisioned Terafab, early steps in an audacious and likely arduous attempt to break into the production of cutting-edge chips. Staff working for the joint venture between Tesla Inc and Space Exploration Technologies Corp (SpaceX) have sought price quotes and delivery times for an array of chipmaking gear, people familiar with the matter said. In past weeks, they’ve contacted makers of photomasks, substrates, etchers, depositors, cleaning devices, testers and other tools, according to the people, who asked not to
Japan approved ￥631.5 billion (US$3.97 billion) in additional subsidies to hasten Rapidus Corp’s entry into the high-stakes artificial intelligence (AI) chipmaking arena, ramping up support for a project widely regarded as a long shot. The capital is intended to bankroll Rapidus’ work for information technology firm Fujitsu Ltd, one of the initial customers that Tokyo hopes would get the signature endeavor off the ground. The new money raises the fees and investments that the government is injecting into the start-up to ￥2.6 trillion by the end of the current fiscal year to March next year, the Japanese Ministry of Economy, Trade and
RSS